KRAS mutations lie at the core of colorectal cancer (CRC) pathogenesis, driving persistent activation of the MAPK/ERK and PI3K/AKT pathways and conferring resistance to numerous therapies, particularly anti-EGFR antibodies. The gene discussed is KRAS; the disease is colorectal carcinoma.